They act as irreversible EGFR inhibitors, effectively managing cancer progression induced by EGFR-TKI-sensitive and T790M-resistant mutations, with an added advantage of controlling brain metastases (Cross et al., 2014; Remon and Planchard, 2015; Anand et al., 2019). This evidence concerns the gene EGFR and cancer.